The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, as well as the growing importance of technologies such as such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Antibody serum stabilisers.

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Antibody serum stabilisers is a key innovation area in pharmaceuticals

Antibodies have a multitude of applications due to their high specificities but are sensitive to denaturation under higher working temperature. An antibody stabiliser contains additives for conservation of structure of proteins and antibodies in solution. Proteins and antibodies are, thus, prevented from losing functionality by storage.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 90+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of antibody serum stabilisers.

Key players in antibody serum stabilisers – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to antibody serum stabilisers

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
F. Hoffmann-La Roche 1198 Unlock company profile
AbbVie 333 Unlock company profile
Regeneron Pharmaceuticals 308 Unlock company profile
Amgen 298 Unlock company profile
Takeda Pharmaceutical 241 Unlock company profile
Pfizer 164 Unlock company profile
Jiangsu Hengrui Medicine 152 Unlock company profile
Fresenius 152 Unlock company profile
Bayer 142 Unlock company profile
Merck & Co 131 Unlock company profile
Sanofi 127 Unlock company profile
Prothena 104 Unlock company profile
E. Merck 102 Unlock company profile
Biogen 95 Unlock company profile
UCB 90 Unlock company profile
AstraZeneca 87 Unlock company profile
Johnson & Johnson 70 Unlock company profile
Bristol-Myers Squibb 54 Unlock company profile
MorphoSys 52 Unlock company profile
Innovent Biologics 48 Unlock company profile
Abbott Biotechnology 48 Unlock company profile
GSK 46 Unlock company profile
Abbott Laboratories 44 Unlock company profile
Glenmark Pharmaceuticals 42 Unlock company profile
Biocad 38 Unlock company profile
LFB 38 Unlock company profile
Outlook Therapeutics 35 Unlock company profile
Gedeon Richter 33 Unlock company profile
Biocon 33 Unlock company profile
Zydus Lifesciences 32 Unlock company profile
Celltrion 30 Unlock company profile
Bausch Health Companies 30 Unlock company profile
Eli Lilly and 29 Unlock company profile
Gmax Biopharm 24 Unlock company profile
Samsung Biologics 22 Unlock company profile
15 Seconds of Fame 20 Unlock company profile
Zeria Pharmaceutical 20 Unlock company profile
Innate Pharma 20 Unlock company profile
Japan Chemical Research & Industries 19 Unlock company profile
Cytodyn 19 Unlock company profile
Green Cross Holdings 17 Unlock company profile
Swedish Orphan Biovitrum 17 Unlock company profile
Novo Nordisk Foundation 17 Unlock company profile
C. H. Boehringer Sohn 16 Unlock company profile
Geeks On Call 16 Unlock company profile
Genmab 15 Unlock company profile
Daiichi Sankyo 15 Unlock company profile
Nuclear Threat Initiative 15 Unlock company profile
Adocia 15 Unlock company profile
Catalent 14 Unlock company profile

Source: GlobalData Patent Analytics

F. Hoffmann-La Roche is the leading patent filer for antibody serum stabilisers. The company develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions.

In terms of application diversity, BioNTech is the top company, followed by AbbVie and Pfizer. By means of geographic reach, Nuclear Threat Initiative holds the top position. Catalent and Zeria Pharmaceutical are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.